Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18100018 | 0.95 | TGM2 (0.50) | TGM2TSHRNOD1CASP1SIRT2 | |
| SCHEMBL1273690 | 0.88 | TGM2 (0.47) | TGM2NOD1HDAC2CTSSCTSL | |
| SCHEMBL731863 | 0.87 | TGM2 (0.46) | TGM2NOD1HDAC2CTSSCTSL | |
| SCHEMBL3512595 | 0.87 | TGM2 (0.46) | TGM2NOD1HDAC2CTSSCTSL | |
| SCHEMBL3253857 | 0.86 | TGM2 (0.45) | TGM2NOD1HDAC2CTSK | |
| SCHEMBL11001505 | 0.85 | CASP1 (0.45) | TGM2CASP1 | |
| SCHEMBL7605714 | 0.85 | FOLH1 (0.44) | TGM2CASP1 | |
| SCHEMBL21315776 | 0.85 | FOLH1 (0.44) | TGM2CASP1 | |
| SCHEMBL3311510 | 0.85 | NOD1 (0.46) | TGM2NOD1CTSK | |
| SCHEMBL13679273 | 0.85 | NOD1 (0.46) | TGM2NOD1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879607-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-1879607-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-12 | — | — | EP | disclosed |
| US-7879797-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879797-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090075869-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090075869-A1 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| EP-1879607-A2 | HCV NS3 PROTEASE INHIBITORS | Merck & Co., Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006119061-A2 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075869-A1 | HCV NS3 protease inhibitors | HAVCR2, GTF3C3, CTSC | TGM2 720/4885TSHR 4610/4885NOD1 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.